summary isomers of linoleic acid Fig 1 Two major bioactive acid via biohydrogenation which is naturally present Additionally ClarinolBene31cial Effect of CLA Similar 31ndings are b ID: 940493
Download Pdf The PPT/PDF document "SCIENTIFIC BACKGROUND INFORMATION ON" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
SCIENTIFIC BACKGROUND INFORMATION ON summary isomers of linoleic acid (Fig. 1). Two major bioactive acid via biohydrogenation, which is naturally present • •Additionally, ClarinolBene cial Effect of CLA Similar ndings are being reported in humans, including study, OCOH OCOHOCOHLinoleic acid (C18:2 c9,c12)Conjugated linoleic acid (C18:2 c9,t11)Conjugated linoleic acid (C18:2 t10,c12) Figure 1Chemical structures of linoleic acid and conjugated linoleic acids c9,t11 CLA and t10,c12 CL -0.-0.-0.00.3 0.6 Change in fat mass (kgArmsPlaceboLegsTrunkFigure 2Clarinol® reduces region-specific fat
mass after six months Clarinol® Bene cial Effect of CLA increased lean body mass after six months without any Effect of CLA on Body Composition • • • • •lipase, stearoyl-Co A desaturase, and fatty acid binding Additionally, Clarinolevents such as infection, skin rash, irritability, hair CLA — Safe and Effective Weight Management Aid ® Total CLA dose (g/d)Figure 3Studies show that CLA significantly decreases fat mass in a dose-dependent manner (Whigham et al., 2007) -0.38642-0.1-0.1-0.2-0.2-0.00.050.000.150.10Change in fat mass (kg/wk)relative to placebo Figure 4Clarinol® increa
ses lean body mass -0.400.00-0.200360.400.20 0.800.601.00 Change in lean body mass in kgMonths Clarino®Placebo studies in overweight (2-year, 3.4g/day) and obese (1-year, 6g/day) subjects have con rmed the safety information, an expert panel of independent biomedical with a daily dosage of 1.7g/day to 3.6g/day. • • • •Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein in healthy, overweight humans. Am J of Clin Nutrition, 2004; The information provided in this brochure is intended for educational purposes only, and should not be used as medical advice. The statements herein have no
t been evaluated by the Food and Drug MMJW,Westerterp-Plantengaadverse events after weight loss [Abstract]. FASEB San Vik H, Gudmundsen O. Conjugated linoleic acid healthy overweight humans. Am J Clin Nutr. 2004 Vik H, Gudmundsen O. Supplementation with conjugated body fat mass in healthy, overweight humans. J Nutr. 2005 mass decreases in overweight and obese. Br J Nutr. Whigham L, Watras A, Schoeller D. Ef cacy of conjugated humans. Amer. J. Nutr. 2007; 85:1203-1211. ® STEPAN LIPID NUTRITION USA100 West Hunter AvenueSTEPAN LIPID NUTRITION EUROPE1541 LP, Koog aan de Zaan www.lipidnutrition.comBV